Company / Current Liabilities
Charles River Laboratories Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$1.1B
FY2025
5-year range
$994.1M / $1.1B
FY2021-FY2025
Trend
+12.7%
vs FY2024
Sector context
#47 of 160
Health Care
What the data says
At $1.1B, Charles River Laboratories's current liabilities ranks #114 of 160 in the Health Care sector. Current Liabilities returned to growth in FY2025 after 2 years of decline, reaching $1.1B.
Based on SEC 10-K filings.
$1.1B in FY2025 with a 5-year CAGR of +5.9%.
Increased from $1.1B to $1.1B over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +0.9%
- 5-Year CAGR
- +5.9%
- 10-Year CAGR
- -
Sector benchmark
#114 of 160 in Health CareTop 71% of 160This company $1.1B Sector average $4.5B
▼
-75.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.9%, indicating consistent growth.
- In FY2025, current liabilities increased 12.7% year-over-year.
- Ranks #47 out of 160 companies in the Health Care sector.
- Lowest current liabilities in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1B | +12.7% |
| FY2024 | $994.1M | -5.8% |
| FY2023 | $1.1B | -3.3% |
| FY2022 | $1.1B | +5.7% |
| FY2021 | $1.0B | +23.0% |
| FY2020 | $839.8M | +18.2% |
| FY2019 | $710.2M | +27.2% |
| FY2018 | $558.2M | +20.4% |
| FY2017 | $463.5M | +7.9% |
| FY2016 | $429.6M | +37.8% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026